

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u> Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u> Kind Attn.: Famroze Pochara Asst. Vice President
Date: July 4, 2017	
Re.: Press Release	

Dear Sir / Madam,


We enclose herewith a copy of press release dated July 4, 2017, titled "Zydus' receives tentative approval from the USFDA for Sitagliptin and Metformin Hydrochloride Tablets".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, Cadila Healthcare Limited


Upen H. Shah
Company Secretary



Encl.: As above

Zydus receives tentative approval from the USFDA for Sitagliptin and Metformin Hydrochloride Tablets

Ahmedabad, 4 July 2017

Zydus Cadila has received the tentative approval from the USFDA to market Sitagliptin and Metformin Hydrochloride Tablets in the strengths of 50 mg/500mg and 50 mg/1000mg.

This is a fixed dose combination of two anti-diabetic drugs indicated for Type II diabetes mellitus and will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
